Importantly, it also demonstrates comparable antitumor efficacy in other solid tumors harboring p53 mutations, offering a novel insight into the utilization of MOF-based drug delivery systems for the treatment of a range of refractory cancers through the conditional synthetic lethality (Figure 7). The gene discussed is TP53; the disease is cancer.